Esketamine: A Possible Adjunctive Therapy for Treatment Resistant Depression.
Annie Huang, Jennifer L Fernandez Vasquez, Catherine A Yeager
Journal of the American Board of Family Medicine : JABFM 2025 DOI: 10.3122/jabfm.2025.250369r0 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Interventions | Esketamine Quetiapine |
| Topics | Depression Esketamine |
| Key points | Augmenting current medication therapy with esketamine results in greater rates of remission for treatment resistant depression as compared with quetiapine. |
Abstract
If available in one's practice area, augmenting current medication therapy with esketamine results in greater rates of remission for treatment resistant depression as compared with quetiapine1.